skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Paired-eye comparison of medical therapies for glaucoma

Original Research

(2167) Views  (490) Full article downloads

Authors: Alfred M Solish, Friedericke James, John G Walt, et al

Published Date September 2010 Volume 2010:4 Pages 1131 - 1135
DOI: http://dx.doi.org/10.2147/OPTH.S12161

Alfred M Solish1,2, Friedericke James1, John G Walt3, Tina H Chiang3
1Southern California Glaucoma Consultants, Pasadena CA, USA; 2Jules Stein Eye Institute, University of California Los Angeles, Los Angeles, 3Allergan Inc., Irvine, CA, USA

Objective: To evaluate efficacy and patient preference retrospectively among intraocular pressure (IOP)-lowering prostamide and prostaglandin medications in a real-world clinical setting.
Methods: Chart review of patients with uncontrolled glaucoma or ocular hypertension seen at a private practice clinic (n = 55) who received bimatoprost 0.03% once daily in one eye and either travoprost 0.004% or latanoprost 0.005% once daily in the fellow eye. IOP was evaluated at the initial visit and at a follow-up visit scheduled 4–6 weeks later. At the follow-up visit, each patient discussed the clinical results with their physician, chose which medication they preferred to continue using, and were queried regarding the reason for their choice. This paired-eye comparison method is used routinely in clinical practice to assess clinical response and involve patients in decisions regarding treatment. Change in mean IOP from baseline and patient medication choice were the outcome measures.
Results: Bimatoprost-treated eyes (n = 52) had a mean IOP reduction of 2.7 mmHg and travoprost-treated eyes (n = 47) had an average decrease of 1.7 mmHg (P = 0.230). Bimatoprost significantly reduced mean IOP (from 19.8 mmHg at baseline to 17.1 mmHg at follow-up, P < 0.0001), as did travoprost (from 19.4 mmHg at baseline to 17.7 mmHg at follow-up, P = 0.009). Latanoprost-treated eyes were excluded from the efficacy analysis due to small sample size (n = 5). For continued therapy, patients chose bimatoprost over travoprost by a factor of 2.4 to 1. Of the 15 patients who gave a reason for their choice, 80% said their decision was based primarily on IOP change.
Conclusions: Bimatoprost and travoprost were efficacious in reducing IOP among patients with uncontrolled glaucoma and ocular hypertension. Patients preferred bimatoprost over travoprost when trialed in fellow eyes.

Keywords: bimatoprost, travoprost, latanoprost, prostaglandin, prostamide






Readers of this article also read:

Gamma knife radiosurgery for uveal melanoma ineligible for brachytherapy by the Collaborative Ocular Melanoma Study criteria
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Functional mobility and balance in community-dwelling elderly submitted to multisensory versus strength exercises
The role of clinical parapapillary atrophy evaluation in the diagnosis of open angle glaucoma
Erratum - Intracellular heavy metal nanoparticle storage
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Steroid response pattern and outcome of pediatric idiopathic nephrotic syndrome: a single-center experience in northwest Iran
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Twelve-week, randomized, multicenter study comparing a fixed combination of brimonidine-timolol with timolol as therapy adjunctive to latanoprost
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy